The immunochemiluminometric assay described uses immobilized anti-human parathynn (parathyroid hormone, hPTH)(1-44) and anti-hPTH(44--68) antisera and acridinium ester-labeled anti-hPTH(1-34) to simultaneously measure both intact hPTH and its amino-terminal fragments. Results by the assay correlate well with those by a cAMP-based bioassay and the Nichols Allegro immunoradiometric assay. The minimal detection limit is 0.08 pmol/L. The normal range is 1.0-5.0 pmol/L, and values are higher in older women. About 90% of study patients with surgically proven parathyroid adenomas had abovenormal preoperative PTH concentrations, whereas patients with hypercalcemia of malignancy had normal or suppressed values. This assay was designed to detect both intact PTH and amino-terminal PTH fragments; however, chromatographic fractionation of pools of pnmary and secondary hyperparathyroid plasma showed virtually no amino-terminal fragment activity. Nonetheless, the design is important because the absence of carboxyl-terminal binding sites prevents interference by carboxyl-terminal fragments and because bioactive amino-terminal fragments will react in the assay if they are present in the patients' sera or if they are produced by in vitro proteolysis of intact PTH.
However, the functional activity of the P'FH molecule is related to the amino-terminal portion of the molecule. Assays for monitoring the biological activity of PTH should reliably measure both intact and functional amino-terminal fragments without interference from carboxyl-and mid-molecule fragments or other substances.
Our functional bioassay (bio-PTH) provides such a monitor by using anti-amino-terminal antisera to immunoextract and concentrate both hPTH and the amino-terminal fragments, followed by measurement of their combined activity in stimulating the production of cAMP in cultured osteosarcoma cells (2).
Our goals in developing the current assay were to have an assay that would correlate well with this bio-P'FH assay and also to have an assay that would be easier to perform and would measure lower concentrations of PTH. (A major problem in the development of reliable assays is the low peripheral blood concentration of intact and amino-terminal PrH.) The functional bioassay achieved a measurement sensitivity of 1.0 pmol/L by extracting and concentrating 2.0 mL of plasma; however, this is not sensitive enough to measure subnormal concentrations of the hormone. Therefore, we wanted to develop an assay capable of measuring P'FH concentrations well below the range found in normal subjects.
Key factors in immunoassay sensitivity are the affinity of the antisera, the configuration of the assay, and the specific activity of the detection signal. Brown et al. (3) reported that immunoafflnity-purifled polyclonal antisera were more sensitive than monoclonal antisera for measuring P'FH. Miles and Hales (4) found that immunometric systems based on a combination of immobilized and labeled antibodies were more sensitive than competitive radioimmunoassays with labeled antigens. Ehrlich and Moyle (5) showed that combinations of antisera with affinities for multiple sites on an antigen can effectively increase the binding affinity. In addition, Weeks et al. (6) showed that acridinium esters can produce mmunoassay labels with high specific activities. We have combinea each of these observations to develop a highly sensitive immunochemiluminometric assay (IcMA) that uses a combination of three affinitypurified polyclonal antisera. We evaluated the assay analytically and clinically by comparison with our functional bioassay, by comparison with a commercial immunoradiometric assay, and by measuring PTH in plasma from normal subjects and patients with disorders of PTH metabolism.
MaterIals and Methods

Antisera Production
Three polyclonal anti-hFFH antisera were used in this assay: two attached to the solid-phase capture system and the third for signal detection (Figure 1) . The first antiserum, goat anti-hPTH , is the same as that used for the immunoafilnity extraction system of the bio-PTH assay (2). It was raised by immunizing a goat with synthetic peptide conjugated to bovine serum albumin and by boosting first with conjugated and then with free unconjugated peptide in incomplete Freund's adjuvant. The second antiserum also was raised in a goat by using hPTH(44-68) conjugated to bovine serum albumin as an inimunogen, initially in Freund's complete adjuvant, followed by monthly boosts in incomplete adjuvant. The two goat antisera were affinitypurified with CNBr-activated Sepharose 4B (Pharmacia, Piscataway, NJ) coupled to the same hPTH peptide fragment as was used for immunization. The third antiserum, which was originally raised in sheep immunized with hPTH conjugated to bovine serum albumin, was purchased from Ciba-Corning Diagnostic Corp. (E. Walpole, MA) as affinity-purified antisera labeled with an acridinium ester: 4-(2-succinimidyloxycarbonylethyl)phenyl-10-methylacridiniuxn-9-carboxylate fluorosulfonate.
ICMA Procedure
The assay involves an overnight incubation of 200 L of EDTA-treated plasma specimens with 100 pL of acridinium-labeled antibody, followed by a 3-h incubation with the two goat antisera coupled to polystyrene beads, washing of the beads three times with 1 mL of distilled water, and quantification of the luminescence. The antisera were coupled to the beads by adding a solution containing each of the affinity-purified goat antisera in 0i. mol/L phosphate buffer, 1.0 g per bead, to activated CoBind beads ( to hypoparathyroid plasma to achieve target concentrations of 0.00, 0.05, 0.1, 0.2, and 0.3 pmol/L. We analyzed eight samples of each in five consecutive assays. The mean, SD, and CV were calculated from determinations in duplicate tubes. We calculated the detection limit both as the concentration corresponding to mean + 2.6 SD above the zero pool and as the concentration that had a 99% confidence range exceeding zero, based on linear interpolation of the means and SDs of the measured pools.
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Comparison with an immunoradiometric assay. Plasma from 141 samples was analyzed with both this assay and the Allegro assay (Nichols Institute Diagnostics, San Juan Capistrano, CA) (7) (8) (9) . These samples included 37 specimens from subjects without bone disease, 22 preoperative specimens from patients with surgically proven parathyroid tumors, 12 specimens from patients with chronic renal failure, and 70 miscellaneous specimens. The data were cross-plotted, and Deming regression statistics were calculated for the total and each subgroup. In addition, the standards for both assays were analyzed in the comparison a.ssys. Table 1 is a summary of the cross-reactivities of the
Clinical Evaluations
Specimens from 262 healthy subjects with calcium concentrations 2.52 mmol/L ( 101 mgIL) were annlyzed to establish a normal reference range. The mdividuals were determined nottohave known disorders of calcium metabolism, based on review of their medical records. In addition, we analyzed preoperative spedmens from 110 patients with surgically proven parathyreid tumors, 91 specimens from patients with chronic renal failure, and 10 specimens from patients with hypercalcemia related to malignancy. The data for normal male and female subjects were plotted against subject age, and the 2.5 and 97.5 percentiles were calculated. We determined the distribution of the t results for each group and calculated descriptive statistics.
peptide fragments in the ICMA. The amino-terminal peptides react in the assay but are less potent on a molar basis than hPTH(1-84), with their cross-reactivities varying from 35% to 71%. These peptides had minimal effect on the recovery of hPTH(1-84), for which analytical recoveries were 69% to 97%. The mid-molecule peptide, hPTH(44-68), did not react in this assay and only minimally inhibited the recovery of hPTH(1-84), even at very high concentrations. The carboxyl-terminal peptide did not cross-react in the assay and did not interfere with the recovery of hPTH(1-84), even at very high concentrations. PTH-related peptjde(1-34) had no immunoactivity in this assay.
The dilutions of the samples from four patients with above-normal concentratiOns of PTH paralleled the standard curve. Plots of the expected (x) vs measured (y)
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ChromatographicProfilesof Plasma Pools
Seven plasma pools representing various forms of PTH were fractionated with a 1.5 x 90 cm P-b (BioRad, Richmond, CA) column. The PTH in each fraction was measured with both the ICMA and the bio-PTH assays. The void volume of the columns as measured with Blue Dextran was 65 mL. We made the first two pools by adding synthetic PTH to aged blood-bank plasma. Pool one contained 24 pmol of hPTH per liter, and pool two contained 42 pmol of hPTH(1-84) per liter. Pools three through five were made by combining residual EDTA plasma from patients with renal failure who had above-normal bio-PTH values and increased concentrations of creatimne. Subsequently, we fractionated two additional poo1s, using a second P-b column. Pool six was made by adding both 10 pmol of hPTH(1-84) and 5 pmol of hPTH(1-34) per liter. Pool seven was made by combining residual specimens from patients 
Comparison with Other Assays
The comparison with the bio-PTH assay is illustrated in Figure 3 and Table 2 . Figure 3 displays the b69 data points with values <20 pmol/L in both assays. On the average, the two assays agree well, but there is substantial scatter, particularly at lower concentrations. For normal subjects, the ranges were <b to 6.3 pmol/L in the bioassay and 0.9 to 6.5 pmol/L in the chemiluniinescent in Figure 5 . The approximate central 95% range for healthy younger women and men was 1.0-5.0 pmoIJL. The median value in 87 women younger than 50 years was 2.6 pmol/L, whereas the median in 82 older women was 3.1 pmol/L; the median in 93 men was 2.1 pmol/L. Eleven of the women 50 years had PTH concentrations >5.0 pmol/L, and the lowest value in this age group was 1.6 pmol/L. The age relationships for PTH values in these healthy adults is further illustrated in Figure 6 . No age trend was noted for men, but PTH increased progressively with age in women older than 50 years at an approximate rate of 0.5 pmol/L per decade. Fraction no. same fractions as hPTH . None of the pools contained evidence of immunologically active smaller molecular-mass fragments eluting in the fractions corresponding to hP'FH . For each of the renal failure studies, pools of the three fractions with highest immunoreactivity showed substantial activity on the bio-V1"H assay, whereas pools of fractions corresponding to hPTH(1-34) elution had undetectable bio-PTH activity. Segre et al. (13) , using region-specific antisera and column fractionization techniques, showed that 5-25% of iminunoreactive PT!! in peripheral circulation is intact PTH; they detected no amino-terminal fragments. Boos et al. (14) found a moderate amount of Mr 3400 amino-terminal fragment in parathyroid extracts but relatively low amounts in immunoextracts of peripheral plasmas. Goltzman et al. (15) , using a cytochemical bioassay, found no biologically active aminoterminal fragments in three nonuremic patients with hyperparathyroidism, whereas three uremic patients with secondary hyperparathyroidism and severe skeletal involvement and undergoing chronic hemodialysis had approximately half of their bioactivity as aminoterminal fragments. Nissenson et al. (16), using a renal adenylate cyclase assay, found two peaks of bioactivity in parathyroid venous effluents from each of five patients with hyperparathyroidism.
The first peak corresponded to PTH(1-84), and the second peak was intermediate between and . The variation in these findings may be related to the specificity of the assay systems and the severity of the disease states.
The current assay measures intact PTH best and reacts with amino-terminpl fragments at approximately half potency on a molar basis, but it does not detect mid-molecule or carboxyl-terminal fragments. It is generally agreed that measurement of intact PT!! is the best diagnostic method for parathyroid disorders (1, (7) (8) (9) (17) (18) (19) (20) (21) (22) (23) (24) (25) In addition, the use of antisera to a mid-molecule fragment, hPTH(44-68), instead of carboxyl-terminal antisera, provides further assay robustness by preventing interference by carboxyl-terminal fragments, which may be present in large concentrations in the plasma of patients with renal failure.
Sandwich assays based on antisera against hPTH(53-84) show significant negative interference in the measurement of intact hormone when carboxyl-terminal fragments are present (8). Theoretically, an assay could be designed with only the amino-terminal antisera; however, the hPTH(44-68) region of PT!! is a strong immunological binding site, and inclusion of antisera to this site provides greater analytical sensitivity. In addition, the use of affinity-purified polyclonal antibody instead of monoclonal antibody provides greater assay sensitivity (3). The Ciba-Corning ICMA, which uses monoclonal anti-hPTH(44-68) as the capture antibody on paramagnetic particles and the same hPTH(1-34) signal system as this assay, has a detection limit of only 0.15 pmoIiL (1.4 ng/L) (23) , approximately twice the amount detectable by this assay. The reference range for healthy subjects reported in this study is similar to that for other intact PT!! assays (7, (17) (18) (19) (20) (21) (22) (23) (24) (25) ngfL in the seventh and eighth decades, respectively, in women with use of an assay for intact PT!!; however, they found that these changes were significant only at P = 0.06. Bouillon et a!. (23) reported that 45 healthy elderly men (ages 78 ± 5 years) had intact PTH concentrations not significantly different from those in 94 younger adults (ages 38 ± 11 years). Our data support the increase of PT!! concentration with age in women after age 50 and the constant values of PT!! in men, although we did not test healthy men older than 70.
The published performance of assays of intact PT!! in the diagnosis of primary and secondary hyperparathyroidism has been exceedingly good, with reported detection rates of 97% to 100% (7-9, 18-20, 22-25) . The detection rate found with this assay (9 1%) is lower than that in other reports, but this difference probably reflects the patient distribution used for evaluation rather than the assay performance. with use of Nichols Allegro assay, in which the upper limit of normal was set at 65 ng/L. In a recent editorial in this journal, Nussbaum (31) reported that the National Institutes of Health consensus conference on asymptomatic hyperparathyroidism yielded agreement that immunometric assays measure above-normal concentrations of PTH in 90% of hyperparathyroid patients, and that the remaining 10% of patients have serum PT!!(1-84) values near the upper limit of normal.
This assay has been in clinical use at the Mayo Clinic for the past three years and has had an overall sensitivity of 88% in 361 cases of surgically proven primary hyperparathyroidism (32) . Statistically, the sensitivity of the Mayo ICMA is only slightly better than that found with our mid-molecule/carboxyl-terminal PT!! radioimmunoassay (32) , which had a sensitivity of 86% in 1061 patients with surgically proven parathyroidism (32, 33) .
However, the Mayo IcMA is easier to interpret clinically because the carboxyl-terminal fragments in renal failure do not cause above-normal values. High values in the mid-molecule/carboxyl-terminal radioimmunoassay could be caused by renal failure or hyperparathyroidism, and because some patients have both disorders, it is difficult to assess the pathogenesis of increased PTH concentrations.
However, the mid-molecule/carboxylterminal assay measures the time-averaged metabolic products of PT!!, whereas the Mayo ICMA measures only the short-lived intact and amino-terminal fragments.
Minisola et al. (34) reported falsely normal intact PTH values in patients with mild primary hyperparathyroidism caused by episodic secretion and short halflife of intact PTH. When Kitamura et a!. (35) studied this episodic fluctuation, they found 23 discrete PT!! pulses per day, which caused an average increase of FF1! above nadir of 32%. Harms et al. (36) used spectral analyses to show that the peaks of intact PT!! are concordant with peaks in PTH(44-68), both having maximal spectral power at 45-mm periods, but the spectrum for intact PTH lasted sevenfold longer. These reports illustrate the disadvantage of measuring the rapidly changing biologically active components of PTH rather than the more stable carboxyl-terminal waste products; however, this did not decrease the overall sensitivity for detection of hyperparathyroidism and is substantially offset by the enhanced assay specificity, especially in patients with renal failure.
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